141 related articles for article (PubMed ID: 10882376)
1. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.
Oka M; Matsumoto Y; Sugiyama S; Tsuruta N; Matsushima M
J Med Chem; 2000 Jun; 43(12):2479-83. PubMed ID: 10882376
[TBL] [Abstract][Full Text] [Related]
2. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.
El-Kabbani O; Darmanin C; Oka M; Schulze-Briese C; Tomizaki T; Hazemann I; Mitschler A; Podjarny A
J Med Chem; 2004 Aug; 47(18):4530-7. PubMed ID: 15317464
[TBL] [Abstract][Full Text] [Related]
3. Unusual binding mode of the 2S4R stereoisomer of the potent aldose reductase cyclic imide inhibitor fidarestat (2S4S) in the 15 K crystal structure of the ternary complex refined at 0.78 A resolution: implications for the inhibition mechanism.
Zhao HT; Hazemann I; Mitschler A; Carbone V; Joachimiak A; Ginell S; Podjarny A; El-Kabbani O
J Med Chem; 2008 Mar; 51(5):1478-81. PubMed ID: 18284183
[TBL] [Abstract][Full Text] [Related]
4. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
5. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and aldose reductase inhibitory activity of 2-substituted-6-fluoro-2,3-dihydrospiro [4H-1-benzopyran-4, 4'-imidazolidine]-2',5'-diones.
Yamaguchi T; Miura K; Usui T; Unno R; Matsumoto Y; Fukushima M; Mizuno K; Kondo Y; Baba Y; Kurono M
Arzneimittelforschung; 1994 Mar; 44(3):344-8. PubMed ID: 8192700
[TBL] [Abstract][Full Text] [Related]
7. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
[TBL] [Abstract][Full Text] [Related]
8. Charge density and electrostatic interactions of fidarestat, an inhibitor of human aldose reductase.
Fournier B; Bendeif el-E; Guillot B; Podjarny A; Lecomte C; Jelsch C
J Am Chem Soc; 2009 Aug; 131(31):10929-41. PubMed ID: 19594152
[TBL] [Abstract][Full Text] [Related]
9. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.
Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A
J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934
[TBL] [Abstract][Full Text] [Related]
10. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
Urzhumtsev A; Tête-Favier F; Mitschler A; Barbanton J; Barth P; Urzhumtseva L; Biellmann JF; Podjarny A; Moras D
Structure; 1997 May; 5(5):601-12. PubMed ID: 9195881
[TBL] [Abstract][Full Text] [Related]
11. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
Kato N; Mizuno K; Matsubara A; Nakano K; Kurono M; Yagihashi S
J Diabetes Complications; 1994; 8(1):27-32. PubMed ID: 8167384
[TBL] [Abstract][Full Text] [Related]
12. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.
Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA
Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of fidarestat on aldose reductase and aldehyde reductase activity evaluated by a new method using HPLC with post-column spectrophotometric detection.
Mizuno K; Suzuki T; Tanaka T; Taniko K; Suzuki T
Biol Pharm Bull; 2000 Feb; 23(2):244-8. PubMed ID: 10706394
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase.
Lee YS; Chen Z; Kador PF
Bioorg Med Chem; 1998 Oct; 6(10):1811-9. PubMed ID: 9839011
[TBL] [Abstract][Full Text] [Related]
15. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
El-Kabbani O; Old SE; Ginell SL; Carper DA
Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
[TBL] [Abstract][Full Text] [Related]
16. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site.
El-Kabbani O; Rogniaux H; Barth P; Chung RP; Fletcher EV; Van Dorsselaer A; Podjarny A
Proteins; 2000 Nov; 41(3):407-14. PubMed ID: 11025551
[TBL] [Abstract][Full Text] [Related]
17. Aldose reductase inhibitors.
Oka M; Kato N
J Enzyme Inhib; 2001 Dec; 16(6):465-73. PubMed ID: 12164386
[TBL] [Abstract][Full Text] [Related]
18. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.
Kurono M; Fujiwara I; Yoshida K
Biochemistry; 2001 Jul; 40(28):8216-26. PubMed ID: 11444967
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats.
Obrosova IG; Minchenko AG; Vasupuram R; White L; Abatan OI; Kumagai AK; Frank RN; Stevens MJ
Diabetes; 2003 Mar; 52(3):864-71. PubMed ID: 12606532
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
Singh SB; Malamas MS; Hohman TC; Nilakantan R; Carper DA; Kitchen D
J Med Chem; 2000 Mar; 43(6):1062-70. PubMed ID: 10737739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
